Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-065741
Filing Date
2025-05-07
Accepted
2025-05-07 16:27:33
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tnya-20250331.htm   iXBRL 10-Q 2140817
2 EX-31.1 tnya-ex31_1.htm EX-31.1 22858
3 EX-32.1 tnya-ex32_1.htm EX-32.1 10339
  Complete submission text file 0000950170-25-065741.txt   8069473

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20250331.xsd EX-101.SCH 1178686
69 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20250331_htm.xml XML 1238627
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40656 | Film No.: 25921862
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)